Chordoma

Kronos Bio Reports Recent Business Progress and Third-Quarter 2023 Financial Results

Retrieved on: 
Monday, November 13, 2023
Safety, SAN, D, Carcinoma, Sarcoma, Investment, PD, Cohort study, Patient, Research, Chordoma, Lung cancer, Conference, KRON, Ovarian cancer, Cancer, Mechanism of action, AACR, Genentech, Life insurance, Rare-earth element, Pharmaceutical industry

SAN MATEO, Calif., and CAMBRIDGE, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today reported recent business progress and third-quarter 2023 financial results.

Key Points: 
  • $198.4 million in cash, cash equivalents and investments as of September 30, 2023
    SAN MATEO, Calif., and CAMBRIDGE, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today reported recent business progress and third-quarter 2023 financial results.
  • “This quarter, we made great strides in advancing our clinical programs as well as our discovery projects and Genentech collaboration,” said Norbert Bischofberger, Ph.D., president and chief executive officer of Kronos Bio.
  • Kronos Bio expects that these efforts, which include a 19% reduction in force, will extend its cash runway into 2026.
  • Net Loss: Net loss for the third quarter of 2023 was $31.4 million, or $0.54 per share, including non-cash stock-based compensation expense of $6.3 million.

BostonGene Announces Three Abstract Acceptances at ESMO Congress 2023

Retrieved on: 
Tuesday, October 17, 2023
Research, Genetics, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, TME, Tumor microenvironment, Abstract, DNA, ESMO, IE, Chordoma, Nucleic acid thermodynamics, Liquid biopsy, Patient, Pharmaceutical industry, Vaccine

BostonGene , a leading provider of AI-based molecular and immune profiling solutions, announced today that it will present three abstracts at ESMO Congress 2023 .

Key Points: 
  • BostonGene , a leading provider of AI-based molecular and immune profiling solutions, announced today that it will present three abstracts at ESMO Congress 2023 .
  • The event will be held on October 20 - 24, 2023, in Madrid, Spain, at the IFEMA MADRID.
  • BostonGene will also exhibit in Hall 5, booth 550.
  • To learn more or to schedule a meeting with BostonGene during the event, please contact Maria Proia at [email protected] .

Kronos Bio Presents Positive Preliminary Data from Phase 1 Dose Escalation Portion of Phase 1/2 KB-0742 Study at AACR-NCI-EORTC

Retrieved on: 
Friday, October 13, 2023
Cancer, Lung cancer, Sarcoma, City of Hope National Medical Center, Drug, M.D, Plasma, Vomiting, Breast, AACR, PIN, CDK9, Safety, Half-life, Nausea, Therapy, RECIST, City, Neutropenia, Fatigue, KRON, Chordoma, Mechanism of action, SAN, Patient, Lung, Q&A, Neoplasm, PR, Cmax, Conference, Myxoid liposarcoma, Pharmaceutical industry

The preliminary analysis included 28 patients enrolled in a dose escalation study who received doses from 10 mg up to 60 mg (data cut-off September 1st, 2023).

Key Points: 
  • The preliminary analysis included 28 patients enrolled in a dose escalation study who received doses from 10 mg up to 60 mg (data cut-off September 1st, 2023).
  • KB-0742 also demonstrated dose proportional exposure and target engagement and a 24-hour plasma half-life, enabling intermittent dosing.
  • Because the maximum tolerated dose has not yet been identified, enrollment in the dose escalation portion continues and dosing of patients at the 80 mg dose level is underway.
  • “These positive preliminary efficacy and safety data underscore the promise of KB-0742 to treat patients with transcriptionally addicted tumors.

Axsome Therapeutics Appoints Dr. Sue Mahony to its Board of Directors

Retrieved on: 
Wednesday, October 11, 2023
Aston, Eli Lilly and Company, Acquisition, Doctor of Philosophy, Amgen, Drug development, Business, London School of Management Education, Central nervous system, MD, Organization, University, Mahony, Patient, Chordoma, Therapy, CSL Limited, Schering-Plough, Marketing, Master of Business Administration, Business administration, CNS, CSL Vifor, Horizon Therapeutics, London School of Business and Finance, Pharmaceutical industry, Management, Pharmacy, Philosophy, Lilly, Science

Dr. Mahony most recently served on the board of directors of Horizon Therapeutics from 2019 until its acquisition by Amgen in October 2023.

Key Points: 
  • Dr. Mahony most recently served on the board of directors of Horizon Therapeutics from 2019 until its acquisition by Amgen in October 2023.
  • “We are pleased to welcome Dr. Mahony, who has extensive leadership experience in global drug development and commercialization, to our board of directors,” said Herriot Tabuteau, MD, Chief Executive Officer of Axsome.
  • Dr. Mahony served on the board of directors of Vifor Pharma from 2019 until its acquisition by CSL Limited in 2022.
  • Dr. Mahony also serves on the board of directors of the Chordoma Foundation, a nonprofit dedicated to improving the lives of people affected by chordoma.

WebMD Announces 16th Annual 2023 Health Heroes

Retrieved on: 
Wednesday, October 11, 2023
Diagnosis, Neuroscience, COVID-19, Osteochondrodysplasia, Skull, Bias, Family, The Children's Hospital, Machine learning, MS, Headache, COVID, Driving Force, Sickle cell disease, Rickets, Hospital, Bone tumor, Heart Trouble (album), CDC, Genetics, Disease, WHO, Patient, World Health Organization, Chordoma, Movement, Education, Long, CRISPR, HCA Healthcare, Clinical trial, Duke Cancer Institute, Public policy, Duke University, Genetic disorder, King Fahad Specialist Hospital Dammam, Bangladesh Technical Education Board, Jansen, Tissue, Volunteering, Korea Disease Control and Prevention Agency, Grey, Child, National Institutes of Health, Sarah Cannon Research Institute, Life, WebMD, Research, NIH, Cognitive science, Nursing, Pharmaceutical industry, Vaccine, MD, Long COVID

NEWARK, N.J., Oct. 11, 2023 /PRNewswire/ -- WebMD announced today the winners of the 2023 WebMD 16th annual Health Heroes Awards, which includes 4 categories: Lifelong Advocate, Patient Pioneer, Selfless Survivor and Driving Force.

Key Points: 
  • NEWARK, N.J., Oct. 11, 2023 /PRNewswire/ -- WebMD announced today the winners of the 2023 WebMD 16th annual Health Heroes Awards, which includes 4 categories: Lifelong Advocate, Patient Pioneer, Selfless Survivor and Driving Force.
  • "This year's Health Heroes are not only doing amazing things but they also have data or other measurable results that demonstrate the impact of their work," said Dr. John Whyte, Chief Medical Officer of WebMD.
  • With their findings in hand, they began meeting with public health leadership at the Centers for Disease Control and Prevention (CDC), National Institutes of Health (NIH), and World Health Organization (WHO) to forge a path toward more research on Long COVID.
  • For additional information on the 2023 WebMD Health Heroes, click here: https://www.webmd.com/healthheroes/default.htm

NICO Awards $50,000 Grant to Better Understand the Biological Weakness of Rare Chordoma Tumors

Retrieved on: 
Thursday, September 21, 2023
University, Chordoma, APS, Crystal skull, Spinal cord, Survival, Cancer, Quality of life, Spine, Hope, IIS, Research, Artery, MS, PDX, DSM-IV codes, University of Pittsburgh Medical Center, NICO, Neurosurgery, Patient, Physician, MIPS, Growth, UPMC, Neoplasm, Recurrence, Environment, Disease, Pharmaceutical industry, Medical imaging, Dentistry, MD

INDIANAPOLIS, Sept. 21, 2023 /PRNewswire/ -- Zachary C. Gersey, MD, MS, neurosurgery resident at the University of Pittsburgh Medical Center, has been awarded a $50,000 Investigator Initiated Study (IIS) grant from NICO Corporation. The study aims to determine if immediate biological preservation of patient-derived chordoma tumor tissue, collected intraoperatively and implanted for serial sampling in translational research, will provide new insights into the biological weakness of the disease and contribute to developing improved treatment therapies.

Key Points: 
  • If we are able to further understand the drivers for chordoma recurrence, we may be able to treat recurrences better.
  • The technologies together enable freshly resected chordoma tissue to be harvested and immediately implanted into hosts to study the molecular characteristics of chordoma regrowth in a controlled setting.
  • The goal is to develop a working chordoma PDX model using tissue obtained from NICO technologies.
  • "The pressing need remains for better treatments for chordoma patients," said Josh Sommers, co-founder and executive director of the Chordoma Foundation .

Kronos Bio Reports Recent Business Progress and Second-Quarter 2023 Financial Results

Retrieved on: 
Tuesday, August 8, 2023
PK, Carcinoma, Drug development, PD, Senior, Investment, Sarcoma, Chordoma, Cancer, Pharmacokinetics, Cohort study, Lung cancer, KRON, Patient, SAN, Regulatory affairs, Research, Ovarian cancer, Therapy, Conference, Safety, D, Life insurance, Rare-earth element, Pharmaceutical industry, Medical imaging, Generic drug, Insurance

SAN MATEO, Calif. and CAMBRIDGE, Mass., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today reported recent business progress and second-quarter 2023 financial results.

Key Points: 
  • $219.7 million in cash, cash equivalents and investments as of June 30, 2023, providing expected cash runway into 2H 2025
    SAN MATEO, Calif. and CAMBRIDGE, Mass., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today reported recent business progress and second-quarter 2023 financial results.
  • In June 2023, Kronos Bio announced the appointment of Marc Besman, Ph.D., as Senior Vice President of Regulatory Affairs and Clinical Quality Assurance.
  • G&A Expenses: General and administrative expenses were $11.4 million for the second quarter of 2023, which includes non-cash stock-based compensation expense of $3.8 million.
  • Net Loss: Net loss for the second quarter of 2023 was $29.7 million, or $0.52 per share, including non-cash stock-based compensation expense of $6.9 million.

Kronos Bio Reports Recent Business Progress and First-Quarter 2023 Financial Results

Retrieved on: 
Wednesday, May 10, 2023
Carcinoma, Amgen, Gilead Sciences, Drug development, Investment, Sarcoma, Chordoma, Cancer, Cohort study, Bristol Myers Squibb, Genentech, Lung cancer, KRON, Development, Convatec, AML, Eli Lilly and Company, Celgene, Patient, SAN, Hematology, Merck, Merck & Co., Research, Ovarian cancer, D, Pharmaceutical industry, Commercial property, Rare-earth element, Life insurance

SAN MATEO, Calif. and CAMBRIDGE, Mass., May 10, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today reported recent business progress and first-quarter 2023 financial results.

Key Points: 
  • We continue to recruit significant talent, most recently with the addition of Katherine and Roger to our Board of Directors.
  • Additional data from the Phase 1/2 study, including initial anti-tumor activity, are expected in the second half of 2023.
  • In April 2023, Kronos Bio announced the appointment of Katherine Vega Stultz and Roger Dansey, M.D., to its Board of Directors.
  • Net Loss: Net loss for the first quarter of 2023 was $26.2 million, or $0.46 per share, including non-cash stock-based compensation expense of $6.6 million.

Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2022 Financial Results

Retrieved on: 
Wednesday, March 15, 2023
Society, Investment, Cancer, Research, Roche, D, Chordoma, Lung cancer, SAN, KRON, Patient, Agreement, Cohort study, ASH, Sarcoma, Ovarian cancer, SYK, AML, Carcinoma, MYC, Pharmaceutical industry, Cryptocurrency, Genentech

SAN MATEO, Calif. and CAMBRIDGE, Mass., March 15, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today reported recent business progress and fourth-quarter and full-year 2022 financial results.

Key Points: 
  • For the full year of 2022, research and development expenses were $93.7 million, which includes non-cash stock-based compensation expense of $15.0 million.
  • For the full year of 2022, general and administrative expenses were $43.4 million, which includes non-cash stock-based compensation expense of $16.2 million.
  • Net Loss: Net loss for the fourth quarter of 2022 was $31.8 million, or $0.56 per share, including non-cash stock-based compensation of $7.7 million.
  • Net loss for the full-year 2022 was $133.2 million, or $2.37 per share, including non-cash stock-based compensation expense of $31.1 million.

Kronos Bio Announces Selection of Recommended Phase 2 Dose for its Oral CDK9 Inhibitor, KB-0742, After Reaching Target Engagement Goal with Acceptable Safety Profile in Ongoing Phase 1/2 Clinical Trial

Retrieved on: 
Wednesday, December 7, 2022
SYK, Squamous cell carcinoma, Cohort study, CDK9, Enzyme, Bio, Chordoma, Sarcoma, SAN, Security (finance), Ovarian cancer, RNA polymerase II, RNA polymerase, Cancer, Cmax, Large-cell lung carcinoma, MYC, KRON, Research, Plasma, PK, Kronos, Drug, COVID-19, CDK, Patient, Pharmaceutical industry

SAN MATEO, Calif. and CAMBRIDGE, Mass., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that data from the ongoing dose-escalation stage of its Phase 1/2 clinical trial of KB-0742, the company’s cyclin dependent kinase 9 (CDK9) inhibitor being developed to treat MYC-amplified and transcriptionally addicted solid tumors, support a recommended Phase 2 dose (RP2D) of 60 mg.

Key Points: 
  • This level of target engagement is consistent with demonstrating anti-tumor activity based on preclinical models.
  • A total of 26 patients have been enrolled and treated in the dose escalation phase of the study.
  • The long plasma half-life enables KB-0742 to achieve sustained pharmacologically active concentrations while avoiding potentially toxic peak (Cmax) concentrations.
  • Kronos Bio is a biopharmaceutical company that is advancing two investigational compounds in clinical trials for patients with cancer.